Distinct from current FDA-approved anti-PD-1s, GNUV201 shows h/m cross-reactivity, improved hPD-1 binding kinetics, especially in low pH, and strong tumor regression efficacy in the B16F10 mouse syngeneic melanoma model. Here, PDCD1 is linked to neoplasm.